Tissue Engineering Market Growth Factors
Requirement of organ transplants tissue engineering in the future
The growing need for organ transplants worldwide can be met by tissue engineering and regenerative medicine. The development of tissue signaling and vascularization, which would imitate the activities of the original organs, is currently ongoing. To meet the need for organ transplants, there is a better chance of successfully creating complex tissues and entire organs. For instance, tissue engineering regeneration and bioprinting technologies have been used to develop human liver prototypes. Due to the high number of products in the pipeline that are undergoing various clinical trials and are anticipated to be marketed in the future, there is a significant opportunity for the commercialization of tissue-engineered goods.
Technological developments in medical equipment
Technology advancements in medical equipment have revolutionized regenerative medicine and tissue engineering. To supply equipment to the markets for organ regeneration, tissue engineering, and regenerative medicine, several businesses have achieved revolutionary advancements. Furthermore, the commercialization of cutting-edge surgical tools has facilitated the accessibility and simplification of regenerative medicine operations. For instance, the 5210 BioDynamic System and 5270 BioDynamic System from Bose Electroforce provide sterile environments for tissue engineering. Regenerative medicine and tissue engineering are currently on the commercial market thanks to developments in medical automation technology.
Market Restraining Factors
Products made from tissue engineering are quite expensive
The high cost of tissue engineering limits market expansion. Due to a monopolistic environment and the limited supply of tissue-designed products, the emerging tissue engineering business needs help to overcome difficulties. Because there is less competition among suppliers, these services are more expensive. Organ failures and flaws in the US cost more than 400 billion USD annually, demonstrating the market's potential. Due to the high cost of therapy, there is little demand for tissue engineering in developing nations, which restrains the market's expansion.
Market Opportunities
Rising incidence of chronic conditions and trauma emergencies
The use of tissue-engineered products has expanded as the frequency of trauma injuries has increased. The market's expansion is also fueled by an increase in the frequency of accidents, burn injuries, and other trauma injuries. According to the Centers for Disease Control and Prevention, 120,859 deaths were attributed to unintentional injuries in the United States in 2016, of which 26,009 were accidental deaths and 33,687 were fatal motor vehicle accidents.
In addition, the prevalence of accident-related trauma cases is rising, accelerating the global uptake of tissue-engineered goods. The tissue-engineered trauma injury products market has seen many businesses increase their market share. The market for tissue-engineered goods is anticipated to expand quickly during the projected period as technology for accidental care units is expected to advance.
Regional Insights
North america: dominant region with 13.35% market share
North America is the major revenue contributor and is expected to grow at a CAGR of 13.35% during the forecast period. Due to the wide availability and accessibility of tissue engineering products and the significant presence of essential businesses and research institutions, North America strongly relies on tissue engineering technologies. The majority of tissue-engineered product producers are based in North America, particularly in the United States. The regional offices of the world's largest tissue engineering companies, including AbbVie Inc., Becton, Dickinson and Company, Organogenesis Holdings, and Zimmer Biomet, are located here.
Europe: fastest growing region with the highest cagr
Europe is expected to exhibit a CAGR of 14.90% during the forecast period. Germany, France, the United Kingdom, Italy, Spain, and the rest of Europe are the five major European nations taken into account in the report. In 2019, this area held the second-largest market share for tissue engineering worldwide. Due to the region's availability of tissue-engineered products, high demand for tissue-engineered products, and the substantial presence of R&D laboratories and essential enterprises, the tissue engineering market in European countries is anticipated to expand steadily throughout the forecast period. The region's tissue engineering market is expected to increase due to the significant presence of players like B Braun and Tissue Regenix.
China, Japan, Australia, India, South Korea, and the rest of Asia-Pacific are all included in Asia-Pacific. The tissue engineering market has plenty of attractive chances in this area, expected to develop at the fastest rate over the forecast period. The rising demand for advanced healthcare services in developing nations, the development of the R&D sector, and the increased presence of significant players in the region all contribute to the market expansion in this region. Additionally, the industry has developed quickly due to expanding healthcare infrastructure and an emphasis on regenerative medicine. Japan has the most significant impact on the pharmaceutical and biotechnology industries among the Asia-Pacific nations, whereas China has the fastest-growing GDP.
Africa, the Middle East, and Latin America all makeup LAMEA. It had 3.86% of the worldwide tissue engineering market in 2019 and is anticipated to have sizable growth potential. Due to a paucity of tissue engineering goods, advanced healthcare infrastructure, and qualified medical personnel, the tissue engineering industry in LAMEA is still in its infancy. Due to increased knowledge of tissue engineering products in the region, LAMEA is progressively developing into a valuable tissue engineering market. Most Middle Eastern and Latin American nations, particularly Brazil, Argentina, Mexico, Chile, Saudi Arabia, Turkey, and Uruguay, exhibit sustained and ongoing growth in their investments in science and technology as a share of GDP.
Tissue Engineering Market Segmentation Analysis
By product
The market is bifurcated into synthetic scaffold material, biologically derived scaffold material, and others. The biologically derived scaffold material segment is the highest contributor to the market and is estimated to exhibit a CAGR of 13.20% during the forecast period. Collagen, alginate, proteoglycans, chitin, agarose, matrigel, and chitosan are only a few biologically derived materials employed in constructing scaffolds. The biologically generated scaffold materials segment is divided into collagen and other types based on the kind. The chemical makeup of biologically generated scaffolding materials for tissue engineering varies. Polypeptides, polysaccharides, polyesters, and inorganic components make up these substances. Chitosan is a fully or partially deacetylated chitin used to manufacture various tissue-engineered products, including vascular grafts, skin, bone, and cartilage. Xenogeneic materials come from diverse kinds of organisms, resulting in different cell types that can be employed in tissue transplants.
Widespread usage of synthetic biomaterials with specific compositions, microstructures, and long-term repeatability is utilized to replace or repair injured musculoskeletal system components. Synthetic scaffolds are made from synthetic polymers, ceramics, metals, and bioglasses. These biomaterials are employed in treatments including grafting, cementing, dental restorations, and others of a like nature. Depending on their capacity to form a direct link with native tissues after implantation, these materials can be bioinert, bioactive, or bioresorbable. After implantation, bioinert materials, including alumina, zirconia, titanium, and its alloys, do not affect the tissues around them. Bioactive materials like bioglasses and ceramics that directly bind with live tissues are used to correct minor bone flaws and periodontal abnormalities.
By aapplication
The market is bifurcated into orthopedics and musculoskeletal, neurology, cardiovascular, skin and integumentary, dental, and others. The orthopedics and musculoskeletal segment owns the highest market and is estimated to exhibit a CAGR of 13.20% during the forecast period. The musculoskeletal and orthopedic systems provide support, stability, and movement. It consists of the skeleton's bones, muscles, cartilage, tendons, ligaments, and connective tissues that hold the body's organs in place and provide support. Tissue engineering is used to repair and replace the meniscus, cartilage tendons, and bone tissues in orthopedic and musculoskeletal procedures. The most potential applications of musculoskeletal tissue engineering are in bone and cartilage repair and replacement.
Globally, cardiovascular illnesses are the leading cause of death. Because the heart's ability to regenerate is limited, transplantation may be the sole option in some circumstances, albeit having significant drawbacks. Tissue engineering is therefore viewed as the best strategy in cardiology. Cardiac tissue engineering mainly entails cardiac grafts, such as tissues, and the regeneration of tissues without creating side effects like immunogenicity. The most common biomaterials for heart regeneration are polymers, which include synthetic, natural, and combination materials. Polyglycolic acid (PGA), polylactic-l-acid (PLLA), and polylactic glycolic acid (PLGA) polyurethane are examples of synthetic polymers utilized for cardiac tissue engineering.
Tissue-engineered products for treating burns, chronic wounds, and wounds following cosmetic surgery are included in the skin and integumentary sector. The most frequent cause of skin abrasion is thermal damage. In the United States, there are one million hospital emergencies related to thermal injuries yearly. Skin loss can also result from trauma, persistent ulceration, and thermal burns. Doctors face difficulties when treating burn victims. Various skin tissue engineering techniques, such as skin tissue grafting, are used to treat burns. Grafting one's bodily tissue is not an option if the burn damage is more significant than 90%. In these situations, medical professionals attempt to cultivate epidermal tissues in vitro by giving nutrient-rich supplements.
Simple tooth decay too extensive oncologic craniofacial excision are all examples of dental deformities. To maximize the growth of a single tissue, the hybrid organ in dentistry, it is vital to identify suitable scaffolds and cell sources. Regeneration of teeth, oral mucosa, salivary glands, bone, and periodontium are all included in dental tissue engineering. Additionally, this portion considers tissue regeneration for the alveolar bone, periodontal ligament, enamel, dentin, and entire tooth. Additionally, cells must be given the proper spatial and temporal cues to permit growth, differentiation, and the production of an extracellular matrix with an adequate volume and functional integrity to engineer functional tissues.
Applications of tissue engineering in ophthalmology, gastrointestinal disorders, obstetrics, and other soft tissues are included in the other segments. Products from ocular tissue engineering have great potential for treating or repairing ocular tissues. Research has been conducted to provide ground-breaking techniques for treating various eye disorders, including glaucoma, corneal disease, age-related macular degeneration (AMD), and ocular cancer. After transplantation, engineered biomaterials encourage the survival and functional proliferation of neurons. Additionally, the transplantation of stem cells and tissue grafts into the retina is done to help the recipient develop useful neural connections after the transplant.
By end user
The market is bifurcated into hospitals, specialty clinics, academic & research institutes, and others. The hospitals segment dominates the tissue engineering market by end user due to their comprehensive capabilities in providing advanced medical treatments and conducting complex surgeries that often require tissue engineering solutions. Hospitals are suitable to adopt and integrate tissue-engineered products and therapies because they have the specialized technology, infrastructure, and trained medical experts needed. Additionally, they have the capacity to manage a high volume of patients, ensuring that innovative treatments reach a larger population, further driving the adoption of tissue engineering technologies in these settings.
